Join the All of Us Research Program...
The All of Us research program, part of the Precision Medicine Initiative through the National Institutes of Health (NIH), is an...
Randomized Trial to Evaluate SPI-2012 Versus Pegfilgrastim in the Management of Chemotherapy Induced Neutropenia in Breast Cancer Patients Receiving Docetaxel and Cyclophosphamide (TC) (ADVANCE).
The purpose of the study is to investigate an experimental drug called SPI-2012. The purpose of this study is to compare SPI-2012 and pegfilgrastim, while receive chemotherapy with docetaxel and cyclophosphamide (also called TC chemotherapy) for early stage breast cancer. Pegfilgrastim, also known as Neulasta is an approved drug that increases the number of white blood cells in your body.
Contact Candace LeBlanc 508-556-5431 or Marcy Kirkpatrick 508-556-5429 for more information.
For more information about this study: